諾輝健康:已完成30個省市自治區超過400家醫院進院
格隆匯12月31日丨“中國癌症早篩第一股”諾輝健康(6606.HK)發出內部新年寄語文章,其中提到,公司非常樂觀全面完成年初制定的銷售目標;幽幽管已在國家藥品監督管理局最後審批中,獲批在即;宮證清將在2022年進入註冊臨牀。文章還提到,在癌症早篩行業,持續研發創新和堅守前瞻性註冊臨牀驗證是公司領跑行業的核心競爭力,2021年公司完成了30個省市自治區400多家醫院的進院工作,常衞清多靶點糞便FIT-DNA檢測技術進入了兩部國家級結直腸癌篩查和診療指南。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.